#1May 2022 IS The Digital Pharmacy that Runs to You mednow 11. Welcome to Mednow It's like having a pharmacy right in your pocket. Get Started Let's get you logged in. mail Address bere mednow Sign + Forgot Password? have an account? Register TSX-V: MNOW OTC-QB: MDNWF#2Notice and Disclaimer This presentation contains "forward-looking information" for purposes of applicable Canadian securities laws ("forward-looking statements"). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations or assumptions regarding the future of our business, future plans and strategies, our operational results and other future conditions. Forward-looking statements can be identified by words such as "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "predict", "project", "seek", "target", "potential", "will", "would", "could", "should", "continue", "contemplate" and other similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include all matters that are not historical facts, and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our operational performance, market opportunities, estimates relating to market growth, the intention to grow the business operations and expand into additional jurisdictions, expected benefits of recently completed acquisitions, planned activities of the Company, future outlook and goals, prospects, strategies and the industry in which we operate. Forward-looking statements are based on our current expectations, beliefs, assumptions, estimates and forecasts about the Company's business and the industry and markets in which it operates, including among others, assumptions relating to: (i) the ability of the Company to successfully expand into additional jurisdictions; (ii) that the telemedicine and pharmacy market will grow at the rate expected; (iii) the availability of financing; (iv) that third party contractors and supplies and regulatory approvals required to conduct the Company's planned activities will be available on reasonable terms and in a timely manner; (v) that general business, legislative and economic conditions will not change in a material adverse manner; (vi) that the Company will receive all approvals required to operate and grow its business as planned; (vii) that the Company will be successful in pursuing revenue, operational and other synergies with its recently completed acquisitions; (viii) that the acquisition of Infusicare Canada Inc. will complete as anticipated by management; and (ix) that COVID-19 will not negatively impact the business or personnel of the Company. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. By their nature, forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking statements. This Presentation also contains future-oriented financial information and financial outlook information (collectively, "FOFI") as defined under Canadian securities laws, prepared by Mednow's management about Mednow's reasonably estimated prospective results of operations, revenue, sales, and components thereof, all of which are subject to the same assumptions, risks factors, limitations and qualifications set forth in the above paragraphs. Readers are cautioned that FOFI are not guarantees of future performance, and should not be considered as such, since actual results may differ materially from those expressed in FOFI. Mednow and its management believe that FOFI has been prepared on a reasonable basis, reflecting management's best estimates and judgements. FOFI contained in this Presentation were made as of the date of this presentation and is provided for the purpose of describing the belief of Mednow's management of the anticipated effects of the financing on Mednow's business operations. As a result, there can be no assurance that forward-looking information or FOFI will prove to be accurate, as actual results and future events could differ materially from those anticipated in this Presentation. Accordingly, readers should not place undue reliance on the forward-looking information or FOFI contained in this Presentation. Mednow does not undertake any obligation to publicly update or revise any forward-looking information or FOFI other than as required under applicable securities laws. These risks and uncertainties include, but are not limited to, the failure of the Company to realize the benefits of its expansion plans as expected; the inability of the Company to obtain the capital or approvals, permits or licenses required to achieve its business objectives; unanticipated costs; reliance on key management and other personnel; potential downturns in economic conditions; increased competition; failure to effectively synergize the operations of our recently completed acquisitions; changes in laws and regulations; impact of COVID-19 on the business and personnel of the Company; other risks associated with the Company's industry; and those described in greater detail under "Risk Factors" in the Prospectus. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statement that we make in this presentation speaks only as of the date of this presentation, and, except as required by law, we undertake no obligation to update any forward-looking statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data. Non-IFRS Measures This Presentation refers to certain measures that are not recognized measures under International Financial Reporting Standards ("IFRS"). These measures do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from Mednow's management's perspective. Accordingly, these measures should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS. We use non-IFRS measures, including run-rate revenue, run-rate growth, gross margin, and sales volume. These non-IFRS measures are used to provide investors with supplemental measures of our operating performance and thus highlight trends in Mednow's core business that may not otherwise be apparent when relying solely on IFRS measures.#3mednow | TSX-V: MNOW I OTC-QB: MDNWF Mission We believe all people of Canada should have access to amazing care to help them live their healthiest lives Vision Mednow strives to lead the digital health evolution using our people-first approach with helpful technology, redefining pharmacy's role in holistic care 3#4DOCTORS DIGITAL Mednow is an Integrated Digital Pharmacy Platform PHARMACY mednow I TSX-V: MNOW I OTC-QB: MDNWF HOLISTIC HEALTH ● 1 Pharmacy Owned and Operated Virtual: Access a pharmacist and fill prescriptions from anywhere in Canada by phone or app, with free delivery ¹ Specialty Pharmacy Services: Integrated care models focused on high cost medications 2 Virtual Care Provides Integrated Experience to Facilitate Pharmacy Services • Virtual: Online or telemedicine visit with doctor • At-Home Doctor visits: Doctors visit patients at the patients' homes 3 Holistic Health Services Offering with Curated Tools for Wellness • Holistic services: DNA Testing, Mental Health App, Nutrition Services Hi, Jeremy. Get ahead of your health. We can help you learn more about your body and what's to come. Ⓡ My Prescriptions Shop ก Home Learn More →→ Chat with Maya Last message sent at 2:00p.m. Orders See a Doctor G Profile 1. Currently available in Greater Toronto Area, Greater Vancouver Area, London and Halifax 4#5In 2022, Mednow aims to capitalize on its High Growth Digital Pharmacy Platform with High Barriers-to-Entry Operational Fulfillment Centres Fulfillment Centres in Development Vancouver mednow I TSX-V: MNOW I OTC-QB: MDNWF Calgary Winnipeg F $45M target revenue for 2022 with $100M target revenue by 2023 3 acquisitions bringing $30M in annualized revenue to Mednow Established 6 high volume throughput, multi-thousand script capacity, pharmacies nationwide Scaling patient acquisition through Mednow For Business (™M) and direct-to-consumer lines State-of-the-Art Consumer Facing App on the Apple and Android 60 Employees (Tech, Marketing and Pharmacy) that won 2021 Great Place to Work(™) award Toronto London Montreal Dartmouth 5#6Financial Performance & Key Performance Indicators (KPIs)#7Investment Highlights - 2022 & 2023 Forecasts Show Strong Growth 2022 Calendar Full-Year Forecast $42.5 - $47.5M Revenue 20% Gross Margin Negative Adjusted EBITDA Margin 40K - 45K Active Patients (define with active in last 24 months) mednow I TSX-V: MNOW I OTC-QB: MDNWF 2023 Calendar Full-Year Forecast $105 - $110 M Revenue 25% Gross Margin $5 - $10 Million Adjusted EBITDA 110K - 120K Active Patients (define with active in last 24 months) 1. Adjusted EBITDA is defined as earnings before interest, tax, depreciation and amortization and transaction costs; EBITDA is not a recognized measure under Canadian generally accepted accounting principles; management believes however that Adjusted EBITDA is a useful supplementary measure as it provides indication of the results of Mednow's business operations; please refer to disclaimer on page 2 regarding Non-IFRS Measures. 7#8Legend Investment Highlights - 2022 and 2023 Forecasts Show Strong Growth Doctor Services Pharmacy 1 mednow I TSX-V: MNOW I OTC-QB: MDNWF +2,400% Growth $1.8M $0.7K $1.1M Calendar 2021 +140% Growth $42.5M - $47.5M $3M $42M Calendar 2022 $105M - $110M $5M $102M Calendar 2023 1. Includes other healthcare services and technology 00 8#9Key Fiscal Q2/22 Highlights Strong Revenue and Patient Growth Continues mednow I TSX-V: MNOWIOTC-QB: MDNWF $1.9M Revenue +230% Q/Q ~19K (Jan. '22) Patients Cash Position is Solid and Margins are Strong $16.4M Cash Balance 19% Gross Margin 9#10Legend Doctor Services Pharmacy Forecasted Strong Q3/22 Revenue growth of +175% Q/Q $5M - $5.5M +375% Growth $120K Fiscal Q4/21 mednow I TSX-V: MNOWIOTC-QB: MDNWF +230% Growth $570K $433K $137K Fiscal Q1/22 +175% Growth $1.9M $400K $1.5M Fiscal Q2/22 Fiscal Q3/22 (Estimate) 1. Includes other healthcare services and technology 10#11mednow I TSX-V: MNOW I OTC-QB: MDNWF Active Patients Grew +20% Q/Q 16K Fiscal Q1/22 +20% 19K Fiscal Q2/22 11#12Mednow Trades at a Discount to Peers Based on Price / Sales (trailing 12 months) mednow I TSX-V: MNOW I OTC-QB: MDNWF 5.6x MedAvail 2.9x WELL Health TECHNOLOGIES CORP 1.5x1 Neighbourly Pharmacy As of: February 22, 2022, Source: TMX Money; 1. Pro forma Neighbourly's acquisition of Rubicon 12#13Overview#14Healthcare 2,3,4,5 Education 2,3 2,3 Transportation2 Restaurant2,3 2,3 Accomodation mednow Chegg Technology Has Disrupted Many Consumer Industries 2019 Canadian Industry Expenditures 1 Uber • OpenTable Booking.com felix 0.0 duolingo lyn SKIP DISHES airbnb mednow I TSX-V: MNOW I OTC-QB: MDNWF maple P POCKETPILLS $106B $8B $71B $21B $264B The digital pharmacy sector is ripe for disruption and in early days of consumer adoption in Canada ● Expected ePharmacy compound annual growth rate of (CAGR) of 18.4% from 2021-20286 7 • 64% increase in demand for virtual care • Consumer trends of on-demand pharmacy aligns with virtual healthcare and pharmacy solutions 1. The logos are exclusively used for illustration purposes and have no correlation to the expenditure amounts set forth for each industry. The company makes no representation as to the expenditure amount allocated to each company. 2. This figure represents the total amount spent on this industry in Canada in 2019 3. StatsCan, Spending, Canada, 2019 4. CIHI National Health Expenditure, 2019 5. This represents Mednow's objective. However, there is no guarantee that Mednow will be successful in achieving it 6. Cision PR Newswire: ePharmacy Market Size worth $169.3 Billion By 2028 7. Frost & Sullivan, Telehealth to Experience Massive Growth with COVID-19 Pandemic [...], 2020 14#15Fragmented Pharmacy Market is Ripe for Disruption $264B Annual healthcare expenditure in Canada ¹ $2B Telemedicine Market 3 $47B The Canadian Pharmacy market ² mednow I TSX-V: MNOWIOTC-QB: MDNWF $1,072 Avg. personal pharmacy spend per year 6 30% Gross margin 7 2.8M Telemedicine appointments in Ontario alone in 2020, up 100% 8 30% Gross margin The Digital Pharmacy Sector is Ripe for Disruption • 9800 pharmacies in Canada4 Margins are declining in brick and mortar pharmacies due to the high density of pharmacies in the Canadian market (27 pharmacies per 100K population versus 24 per 100K for the average OECD country and only 10 in the US)5 ● ● Digital pharmacies have the potential to support large volume through automation and central filling 1. CIHI National Health Expenditure, 2019 2. IBISWorld, Pharmacies & Drug Stores in Canada, 2020 3. Fortune Business Insights 4. Statista.com December, 2020 5. OECD 2016 6. CIHI National Health Expenditure, 2019 7. Approximate values based on Mednow West fulfillment centre financial statements as of January 31, 2022, has no relation to the total figures used for the industry as a whole 8. Telemedicine use is rising amid COVID-19 pandemic [...] Global News via Ontario Telemedicine Network (OTN) 9. Based on Medvisit's audited financial statements for the year ended 2020, and has no relation to the total figures used for the industry as a whole 15#16Key Pharmacy Metrics Drive Strong Growth $ $4.7B Total Addressable Market for Digital Pharmacy (assumes 10% of pharmacy spend will be digital) 1 mednow I TSX-V: MNOW I OTC-QB: MDNWF $1K Approximate Average Drug Spend Per Pharmacy Patient Per Year ³ 96% of Canadians Trust Pharmacists to be an Important First Point of Contact for the Health-Care System5 $90 Average Drug Transaction Spend Per Pharmacy Patient 4 18% Expected ePharmacy Compound Annual Growth Rate of (CAGR) from 2021-2028 ² $ 4 % 30% Gross Margin on Retail Drugs (including dispensing fee and markup) 1. IBISWorld, Pharmacies & Drug Stores in Canada, 2020. Assumes 10% of pharmacy spend mall be digital 2.Cision PR Newswire: ePharmacy Market Size worth $169.3 Billion By 2028 3.CIHI National Health Expenditure, 2019 4.Approximate values based on Mednow West fulfillment centre financial statements as of January 31, 2022; has no relation to the total figures used for the industry as a whole 16#17Mednow's Holistic Offering is Unmatched in the Competitive Landscape ¹ TELUS Health Virtual Pharmacy Loblaws POCKETPILLS mednow I TSX-V: MNOW I OTC-QB: MDNWF Neighbourly Pharmacy Pharmacy Doctor Services Ancillary Services thinkresearch Mind Beacon CLOUD DX WELL Health TECHNOLOGIES CORP CloudMD Software & Services Inc. Teladoc HEALTH 1. Based on management's current knowledge and reasonable belief 17#18Mednow's Differentiated Feature Set Provides a Holistic Offering to Patients, Creating High Barriers to Entry Business 18. Prescriptions fulfillment Same day delivery in major cities ¹ In-House virtual & home visit Physician services ² Perfect 5.0 Google Rating ³ 3 Text with your pharmacist All-in-one Digital Application E-commerce offering unique products not available at most pharmacies mednow I TSX-V: MNOWIOTC-QB: MDNWF √ √ √ √ √ √ √ Traditional Brick & Mortar X √ X X X X Grocery & Discount √ X X X X X X Digital Competitors X X X √ X X 5-Star Google Reviews (200+) Telemedicine Competitors X √ X X X X X 1. Currently available in Greater Toronto Area, Greater Vancouver Area, London and Halifax 2. Currently available in the Greater Toronto Area 3. As of February 23, 2022 18#19Accretive Acquisitions Create Significant Synergies in the Mednow Ecosystem General Synergies Infrastructure Synergies mednow Description Key Metrics (last fiscal year) - revenue, profits, patients Cross-Selling - more robust offering to win clients and patients National Expansion Technology - integrate into streamlined technology offering Advanced Capabilities -at-home care / specialty pharmacy services People - adds key primary care and specialist physician roster, patient base and industry relationships I TSX-V: MNOW I OTC-QB: MDNWF Medvisit At-home doctor services $3M revenue, -30% gross margin -15.5K active patients √ √ √ √ InfusiCare Pharmacy that specializes in biologics for rheumatology and gastroenterology $9.3M revenue, -12% gross margin -2.7K active patients √ √ √ Liver Specialty Group Pharmacy that specializes in hepatology and the treatment of liver disease $21.3M revenue, ~10% gross margin -2K active patients √ √ √ ✓ √ 19#20Mednow to Own a National Pharmacy Distribution Network by Q2 2022 € Vancouver Calgary mednow I TSX-V: MNOW I OTC-QB: MDNWF Winnipeg London Toronto Montreal Dartmouth Operational Fulfillment Centres Fulfillment Centres in Development 20#21Really amazed at the level of service I received. Doesn't get much better than this! -Alan Mednow.ca 5.0 ***** 10 Pecheration Sotby stra Larvy Rhod Treview ***** 1 maryam shahoseini Treview photo 17 Paths to Scale - Business to Consumer (B2C) Far and bet 10 LA mednow I TSX-V: MNOW I OTC-QB: MDNWF Lak First time using Mednow and order came right away. This company is amazing! -Ziba A B Patient acquisition engine • Fine-tuned acquisition engine with 50% lower CAC¹ • Test-driven engine, ready for a coming out campaign • An incredible level of care that aims to drive loyalty & referrals¹ 1. This represents Mednow's ongoing business objectives, however there is no guarantee they will be achieved or maintained 2. Mednow.ca's Google reviews 21#22mednow Paths to Scale - Business to Business (B2B) for business mednow for business mednow I TSX-V: MNOW I OTC-QB: MDNWF Company A Preferred Pharmacy program Company B Aims to help reduce cost and improve employee health outcomes Ability to onboard customers en masse Early B2B success "White Label" co-owned pharmacy solution for large organizations tucows PPAO POLICE PENSIONERS ASSOCIATION OF ONTARIO Est. 1997 22#23FF mednow for business Powered by Mednow is a Joint Venture Structure that leverages expansive Mednow pharmacy, logistic and technology assets with large plan sponsors or groups who want to improve their members pharmacy experience and regain control of their spend. We deliver value in three main areas: Mednow Offers a White-Labeled Pharmacy Offering for Large Plan Sponsors Truepill U.S. example of a similar white-label model "Truepill Launches Virtual Pharmacy Platform" https://www.globenewswire.com/news-release/2021/06/04/22 42272/0/en/Truepill-Launches-Virtual-Pharmacy-Platform.html mednow I TSX-V: MNOW I OTC-QB: MDNWF 1 Control & Configurability $ 0 2 Service 3 Transparency & Revenue Stream 23#24Easily Sign Up & Access Care <Login 0% Account Personal Thank you for signing up! Thank you for registering with Mednow. Please check you email to activate your account. We Started with a Vision for the Future of Pharmacy mednow I TSX-V: MNOWIOTC-QB: MDNWF Speak with Care Professionals on Demand < Back How can we help you? Questions about my order Medication or Health Advice Chat History General questions for Mednow > > Disease Specific Programs What health problems are you facing? Help us help you Chronic headaches Stomach pain Dry skin Other > > > Check Ins/ Reminders 9:41 MEDNOW Maya: Hey there! Just checking in to see how your medication plan is going? th ago Free Same Day Delivery mednow Delivery Same Day Delivery Deliver tomorrow Deliver in 2-5 days 24#25Positioned to continue to grow mednow I TSX-V: MNOW I OTC-QB: MDNWF Investment Highlights Full stack healthcare offering through vertical integration A proven management team 25#26Appendix#27mednow I TSX-V: MNOW I OTC-QB: MDNWF Corporate Structure TSX-V Symbol: MNOW OTCQB: MDNWF Market cap: C$14.3M¹ Cash balance: C$16.4³ Share outstanding: 21.6M¹ Options: 3M² Warrants: 0.2M² Insider ownership: ~47% 1. as of May 6, 2022 2. option strike price of $1.71; warrant strike price of $8.50 3. as of January 31, 2022 27#28We are Aiming to Build the Pharmacy of the Future - Our Business Model We aim to create high lifetime value (LTV) customers + subscriptions Digital Pharmacy mednow I TSX-V: MNOW I OTC-QB: MDNWF Prescriptions + Refills Doctor Services Epigenetic testing, Mental Health, Nutrition Holistic Care Dispensing fees Margin on medications Returning high LTV customers + subscriptions Fee per visit direct referrals to pharmacy Fees from ancillary service 28#29Digital Healthcare and Pharmacy is Commanding High Valuations Pill Pack by amazon pharmacy Amazon acquired PillPack for over US$750M¹ in June 2018 AMZN: NASDAQ CAPSULE mednow I TSX-V: MNOW I OTC-QB: MDNWF Raised US$300M at a US$1B valuation in April 2021³ alto Latest financing reportedly with a valuation over $1B4 in January 2021³ ro Raised US$650M currently valued at US$7B in February 20225 The information presented above is comprised of "comparables", which is information that compares Mednow to other issuers. The other issuers in the comparables were included on the basis that they are telemedicine, virtual pharmacy or healthcare companies and are considered to be an appropriate basis for comparison to Mednow because they operate in the same or a similar industry to Mednow. Information about the other issuers in the comparables was obtained from public sources and has not been independently verified by Mednow. There are many risks associated with relying upon the comparables to make an investment decision, including the risk that the performance of Mednow will not necessarily meet or exceed those of the comparable issuers and there is no guarantee that an investor will achieve a return on investment similar to those issuers. If the information concerning the comparables contains a misrepresentation, an investor in Mednow will not have a remedy under securities legislation 1. Amazon.com press release dated June 28, 2018 2. Ro Raises $150 million in Funding - Al Express 3. Digital Pharmacy Capsule Tops $1 Billion.....dated April 28, 2021 4. Reuters: SoftBank leads latest Alto Pharmacy funding..... January 30, 2021 5. Tech Crunch: Existing investors double down on Ro......... February 15, 2022 29#30Karim Nassar CEO & Co-Founder Our Management Team Computer engineer with 15 years of experience in pharmacy, technology, and healthcare logistics leadership. Led retail & specialty pharmacy strategy initiatives at McKesson (MCK: NYSE)) and Innomar Strategies [AmerisourceBergen (ABC: NYSE)]. Bachelor's of Applied Science from the University of Toronto, MBA from Queen's University. Ali Reyhany Director & Co-Founder CEO and Co-Founder, Care Group of Pharmacies (45 locations, $150M revenue'). 20 years' experience in pharmacy, biz dev and operations. BNN Bloomberg and Financial Post "Canada's Top 40 Under 40" 2020. Bachelor of Science - Pharmacy from the University of Toronto. mednow I TSX-V: MNOW I OTC-QB: MDNWF Ben Ferdinand (CPA, CMA, ICD.D) CFO Former CFO at a publicly traded medical health and wellness company, handing over $300M in acquisitions and raising $70M. Served on the boards of CanDeal Inc. and Shorcan Brokers Ltd. MBA from Ivey Business School at the University of Western Ontario. Felipe Campusano Director & Co-Founder Purchased his first pharmacy the day he graduated pharmacy school. Grew a network of over 50 pharmacies and healthcare services. Founder and Chair of Liver Care Canada. Bachelor's of Science, Queen's University, Degree in Pharmacy, University of Toronto. Historical revenue performance and investment success is not indicative of future results 30#31Dr. Karim Vellani Medical Director Computer engineer with 15 years of experience in pharmacy, technology, and healthcare logistics leadership. Led retail & specialty pharmacy strategy initiatives at McKesson (MCK: NYSE)) and Innomar Strategies [AmerisourceBergen (ABC: NYSE)]. Our Advisors Bachelor's of Applied Science from the University of Toronto, MBA from Queen's University. Sim Grewal VP, Technology Computer Science engineer with 13+ years of experience in healthcare technology with a strong focus on execution. Leading the software engineering function at Mednow. Previously, VP Solutions Design at MphRx. mednow I TSX-V: MNOW I OTC-QB: MDNWF Chris Fischer Medical Managing Partner Former CFO at a publicly traded medical health and wellness company, handing over $300M in acquisitions and raising $70M. Served on the boards of CanDeal Inc. and Shorcan Brokers Ltd. MBA from Ivey Business School at the University of Western Ontario. Sean Hurley Fractional Chief Growth Officer Founder and CEO of Pathright Driven $165M in revenue in the last five years. Historical revenue performance and investment success is not indicative of future results 31#32Our Advisors Francis Nwakire Fractional Chief Product Officer Francis is a physician and healthcare technology executive with over a decade of global experience providing clinical care and building technologies that enhance healthcare delivery. Francis has global experience building and managing high-performing product organisations; with a proven track record of successfully bringing great products to market. Francis is currently the Chief Product Officer at Circle, a leading Cardiovascular and Neurovascular-tech company present in 81 countries globally, overseeing product strategy, design and execution. mednow I TSX-V: MNOW I OTC-QB: MDNWF Mahdi Shams Director Partner at MLT Aikins LLP. Advises clients on corporate governance, continuous disclosure obligations, director and officer duties and obligations and general corporate law matters. Kia Besharat Director Senior Managing Director at Gravitas Securities. Director of EMERGE Commerce (ECOM: TSXV). Investment Industry Association of Canada (IIAC) as a Top 40 Under 40 Award Nominee in 2018. 32#33Hello Ciace Supporting the Health of our Customers with Technology Email A Pwed H mednow demente m G 8:00 a tom. Foghat Login + Come with App 10 Continue with Google Don't have an account? Sign Us 00 mednow I TSX-V: MNOW I OTC-QB: MDNWF OF CONTE Wed, Oct 2 SMITH JANE INCLU Vedow ca Breakfast Tue, Oct SMITH JANE PATANON VANWC WARNO ZING GLUCONATE U 08.00 1 20 WEDNOM PHARMACY We GING Helf Using technology to support medication adherence for patients and caregivers 65% of Canadians aged 65+ take two or more medications daily¹ 50% of Canadians with chronic illness do not take their medication properly¹ 1. Canadian Institute for Health Information, Drug Use Among Seniors, 2021 33#34IPO: MNOW (TSXV) C$37M raise Manitoba pharmacy licence acquired Q1 2021 Management Team's Accelerated Development and Milestones in Calendar 2021 Announces Normal Course Issuer Bid Receives direct to consumer (DTC) eligibility Organic growth mednow I TSX-V: MNOWIOTC-QB: MDNWF Nova Scotia fulfillment center goes online 11% equity stake - LS24/7 Mental Health Q3 2021 Police Pensioners Association of Ontario (PPAO), B2B win. 12,000 members Q2 2021 I Mednow Pharmacy West launch Inorganic growth Addition of Benjamin Ferdinand, CFO Mednow Virtual Care launch I TruDiagnostics exclusive Canadian partnership Partnerships Partnership with PACE Consulting I I Awarded 2022 Best Workplace I Marketing agreement with Sterling Capital Brokers Q4 2021 Completion of the acquisition of London Pharmacare and Liver Care Canada Q1 2022 Acquisition of specialty pharmacy InfusiCare Canada Inc. I Agreement to acquire Mednow East Purchase agreement for specialty pharmacy Liver Specialty Group Launches licenced pharmacy in Manitoba T I I Q2 2022 34#35Increases Mednow's Doctor Services Capabilities through Strategic Acquisitions of Medvisit Mednow acquires Medvisit in August 2021 • Medvisit is Canada's largest and longest standing doctor home visit provider • Network of 100 doctors treating acute and episodic illness and injury. 30 years in operation, primarily in the GTA • Multimodal approach to healthcare facilitates the patient experience from diagnosis to prescription delivery Integrates well with Mednow Virtual Care to provide complete medical capabilities to Mednow clients mednow I TSX-V: MNOW I OTC-QB: MDNWF $3M¹ 30K Patient home visits per year 400K Patients in Medvisit database 1. Source: Based on Medvisit's unaudited statement of operations as of July 31, 2021 35#36betakit Mednow.ca's deep industry knowledge coupled with a growing demand for virtual care and pharmacy delivery makes it a very attractive opportunity in the Canadian investment landscape¹ mednow I TSX-V: MNOW I OTC-QB: MDNWF THE GLOBE AND MAIL* Mednow is essentially a virtual pharmacy, offering patients access to pharmacy services via a web-based app or website² In the News RETAIL R.I INSIDER All-Encompassing Virtual Platform Aims to Disrupt Canada's Pharmacy Industry³ BNN Bloomberg An online pharmacy and virtual health provider looking to improve Canadians Health using technology and home delivery4 yahoo! finance Mednow.ca was designed with the best patient experience in mind, it sets a new standard for quality care paired with virtual access to all pharmacy services5 1. Betakit: Mednow.ca raised $6.5 million to connect.........dated July 17, 2020 2. Globe and Mail: Telemedicine company Mednow...........dated March 3, 2021 3. Retail Insider: All-Encompassing Virtual Platform dated December 9, 2020 4. BNN Bloomberg: Canada's Top 40 Under 40......dated October 29, 2020 5. yahoo! finance: Mednow to Begin Trading on TSX......dated March 9, 2021 36#37The Companies Acquired by Mednow Have Produced More Than $33 Million in Annual Revenue in Their Last Fiscal Years mednow I TSX-V: MNOW I OTC-QB: MDNWF 12-month revenue Medvisit $3M August 2021 InfusiCare$ 9.3M November 2021 Liver Specialty Group $21.3M¹ December 2021 mednow $33.6M Source: From the unaudited statement of operations statements for Medvisit, and audited statement of operations for InfusiCare and Liver Specialty Group as of July 31, 2021 37#38Strategic Acquisition of InfusiCare Canada and Liver Specialty Group¹ $9.3M¹ Mednow acquires InfusiCare Canada Inc. Adds specialty pharmacy to Mednow's offering, Biologic drugs make up 42% of patented pharmaceutical sales in Canada² • In 2017, 70% of top selling patented pharmaceuticals were biologic drugs, compared to 10% in 2006³ Expands logistical infrastructure in Southwestern Ontario, by increasing more densely populated cities mednow I TSX-V: MNOW I OTC-QB: MDNWF $21.3M¹ Mednow acquires Liver Specialty Group. • Increases specialty pharmacy services and expertise to include hepatology and the treatment of liver disease. • Services over 20,000 patient visits annually both virtually and in-person • In 2020, hepatitis C medications accounted for the third largest class of drug by percentage of public drug spending in Canada² 1. InfusiCare and Liver Specialty Group Revenue from audited statement of operations as of July 31, 2021 2. Government of Canada Market Trends 3. Patented Medicine Prices Review Board Annual Report 2017 0000 38#39Thank You Investor Relations Contact: Benjamin Ferdinand, CFO [email protected] 1.855.686.6300 https://investors.mednow.ca